SCHEMBL4143797

SCHEMBL4143797

CS(=O)(=O)Nc1ccc(Cl)cc1I

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.46
CCR2 P41597 4/20 0.44
PTGS1 P23219 4/20 0.43
PTGS2 P35354 4/20 0.43
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
NR3C2 P08235 1/20 0.43
AR P10275 1/20 0.43
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
MCL1 Q07820 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
GLO1 Q04760 1/20 0.40
CYP19A1 P11511 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792756 0.82 KIF11 (0.50) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL14906059 0.81 MCL1 (0.61) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL2760253 0.79 MAPT (0.48) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL11560825 0.79 MCL1 (0.59) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL905181 0.78 CCR2 (0.54) KIF11CCR2NR3C1PGRNR3C2
SCHEMBL11562620 0.78 MAPT (0.47) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL13028793 0.78 CA2 (0.41) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4094789 0.78 PTGS2 (0.44) PTGS1PTGS2NR3C1PGRNR3C2
SCHEMBL29904743 0.78 APP (0.54) KIF11CCR2PTGS1PTGS2MAPT
SCHEMBL17338420 0.78 APP (0.54) KIF11CCR2PTGS1PTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846907-B2 Spiro-condensed indoline derivatives as pesticides SYNGENTA CROP PROTECTION LLC (US) 2014-09-30 US disclosed
US-20130046091-A1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES SYNGENTA CROP PROTECTION LLC (US) 2013-02-21 US disclosed
US-8299058-B2 Spiro-condensed indoline derivatives as pesticides SYNGENTA CROP PROTECTION LLC (US) 2012-10-30 US disclosed
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 US disclosed
US-20090042859-A1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2009-02-12 US disclosed
EP-1697376-B1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2008-06-18 EP disclosed
EP-1697376-A1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES Syngenta Participations AG (CH) 2006-09-06 EP disclosed
WO-2005061512-A1 SPIRO-CONDENSED INDOLINE DERIVATES AS PESTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A KIF11 2073/4885CCR2 729/4885PTGS1 1118/4885
US-20090042859-A1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES CHRM1, CHRM2, RO60 KIF11 2668/4885CCR2 368/4885PTGS1 956/4885
US-20130046091-A1 SPIRO-CONDENSED INDOLINE DERIVATIVES AS PESTICIDES CHRM1, CHRM2, CHRM3 KIF11 2673/4885CCR2 420/4885PTGS1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.